Abstract
Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer. We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasive ovarian cancer, and controls were 232 women without ovarian cancer, and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio for developing ovarian cancer was estimated for tubal ligation, adjusting for oral contraceptive use, parity, history of breast cancer, and ethnic group. Findings In an unadjusted analysis among BRCA1 carriers, significantly fewer cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of 173 [35%], odds ratio 0·37 [95% CI 0·21-0·63]; p=0·0003). After adjustment for oral contraceptive use, parity, history of breast cancer and ethnic group, the odds ratio was 0·39 (p=0·002). Combination of tubal ligation and past use of an oral contraceptive was associated with an odds ratio of 0·28 (0·15-0·52). No protective effect of tubal ligation was seen among carriers of the BRCA2 mutation. Interpretation Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing.
| Original language | English |
|---|---|
| Pages (from-to) | 1467-1470 |
| Number of pages | 4 |
| Journal | The Lancet |
| Volume | 357 |
| Issue number | 9267 |
| DOIs | |
| State | Published - May 12 2001 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations : A case-control study. / Narod, Steven A.; Sun, Ping; Ghadirian, Parviz; Lynch, Henry T.; Isaacs, Claudine; Garber, Judy; Weber, Barbara; Karlan, Beth; Fishman, David; Rosen, Barry; Tung, Nadine; Neuhausen, Susan L.
In: The Lancet, Vol. 357, No. 9267, 12.05.2001, p. 1467-1470.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations
T2 - A case-control study
AU - Narod, Steven A.
AU - Sun, Ping
AU - Ghadirian, Parviz
AU - Lynch, Henry T.
AU - Isaacs, Claudine
AU - Garber, Judy
AU - Weber, Barbara
AU - Karlan, Beth
AU - Fishman, David
AU - Rosen, Barry
AU - Tung, Nadine
AU - Neuhausen, Susan L.
PY - 2001/5/12
Y1 - 2001/5/12
N2 - Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer. We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasive ovarian cancer, and controls were 232 women without ovarian cancer, and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio for developing ovarian cancer was estimated for tubal ligation, adjusting for oral contraceptive use, parity, history of breast cancer, and ethnic group. Findings In an unadjusted analysis among BRCA1 carriers, significantly fewer cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of 173 [35%], odds ratio 0·37 [95% CI 0·21-0·63]; p=0·0003). After adjustment for oral contraceptive use, parity, history of breast cancer and ethnic group, the odds ratio was 0·39 (p=0·002). Combination of tubal ligation and past use of an oral contraceptive was associated with an odds ratio of 0·28 (0·15-0·52). No protective effect of tubal ligation was seen among carriers of the BRCA2 mutation. Interpretation Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing.
AB - Background In several case-control and prospective studies, tubal ligation has been associated with a decreased risk of invasive epithelial ovarian cancer. We aimed to assess the potential of tubal ligation in reducing the risk of ovarian cancer in women who carry predisposing mutations in the BRCA1 or BRCA2 genes. Methods We did a matched case-control study among women from Canada, the USA, and the UK who had undergone genetic testing and who carried a pathogenic mutation in BRCA1 or BRCA2. Cases were 232 women with a history of invasive ovarian cancer, and controls were 232 women without ovarian cancer, and who had both ovaries intact. Cases and controls were matched for year of birth, country of residence, and mutation (BRCA1 or BRCA2). The odds ratio for developing ovarian cancer was estimated for tubal ligation, adjusting for oral contraceptive use, parity, history of breast cancer, and ethnic group. Findings In an unadjusted analysis among BRCA1 carriers, significantly fewer cases than controls had ever had tubal ligation (30 of 173 [18%] vs 60 of 173 [35%], odds ratio 0·37 [95% CI 0·21-0·63]; p=0·0003). After adjustment for oral contraceptive use, parity, history of breast cancer and ethnic group, the odds ratio was 0·39 (p=0·002). Combination of tubal ligation and past use of an oral contraceptive was associated with an odds ratio of 0·28 (0·15-0·52). No protective effect of tubal ligation was seen among carriers of the BRCA2 mutation. Interpretation Tubal ligation is a feasible option to reduce the risk of ovarian cancer in women with BRCA1 mutations who have completed childbearing.
UR - http://www.scopus.com/inward/record.url?scp=0035849283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035849283&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(00)04642-0
DO - 10.1016/S0140-6736(00)04642-0
M3 - Article
VL - 357
SP - 1467
EP - 1470
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9267
ER -